Table 15.

Efficacy of 12.5 mg ombitasvir + 75 mg paritaprevir + 50 mg ritonavir fixed-dose two pills QD plus 250 mg dasabuvir BID plus ribavirin for 24w.

Cirrhosis	Prior treatment	SVR12 rate in GT-1	Study and trial phase	Ref.
Cirrhosis	Naïve	1a: 92.9% (52/56), 1b:100% (18/18)	TURQUOISE-II, phase 3	Poordad et al., 2014
	Null response to PegIFNα/RBV	1a:92.9% (39/42), 1b:100% (20/20)
	Partial response to PegIFNα/RBV	1a: 100% (10/10), 1b:100% (3/3)
	Relapse to PegIFNα/RBV	1a: 100% (13/13), 1b:100% (10/10)